FDA Just Fast-Tracked a Vaccine for Alzheimer’s

Giovanni Cancemi/Shutterstock

A vaccine that targets amyloid beta in the brain to treat Alzheimer’s disease has been granted fast-track designation by the FDA.

STORY AT-A-GLANCE

• The U.S. Food and Drug Administration granted fast-track designation to UB-311, a vaccine for Alzheimer’s disease made by biotechnology company Vaxxinity
• Aside from the potential problems that can arise when a vaccine is rushed to market, the vaccine may be problematic from the get-go because amyloid beta may be a symptom of Alzheimer’s, not the cause
• Researchers have even suggested that amyloid beta is a response to neuronal stress, one that functions as a protective adaptation to the disease
• Fast-tracking a vaccine that’s targeting an isolated element of Alzheimer’s disease that is not the underlying cause is destined to be a massive disaster
• Overall, nourishing your brain health is best done with a comprehensively healthy lifestyle, including the use of exercise, ketogenic diet, time-restricted eating, optimized vitamin D and other hormones, increased sleep, meditation, detoxification and elimination of gluten and processed food

The U.S. Food and Drug Administration granted fast track designation to UB-311, a vaccine for Alzheimer’s disease made by biotechnology company Vaxxinity.[1] The shot is an anti-amyloid beta immunotherapeutic vaccine that reportedly treats Alzheimer’s disease by targeting aggregated amyloid beta in the brain.[2]